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Background: Here, we describe the design and characterization of a novel, cryopreserved, viable osteochondral
allograft (CVOCA), along with evidence that the CVOCA can improve outcomes of marrow stimulation for articular
cartilage repair.
Methods: Histological staining was performed to evaluate the CVOCA tissue architecture. CVOCAs were tested
for the presence of extracellular matrix (ECM) proteins and chondrogenic growth factors using ELISA. Cell
viability and composition were examined via live/dead staining, fluorescence-activated cell sorting (FACS)
analysis, and immunofluorescence staining. FACS analysis and a TNF-α secretion bioassay were used to confirm
the lack of immunogenic cells. Effects of the CVOCA on mesenchymal stem cells (MSCs) were tested using
in vitro migration and chondrogenesis assays. The ability of the CVOCA to augment marrow stimulation in vivo
was evaluated in a goat model.
Results: A method of tissue processing and preservation was developed resulting in a CVOCA with pores and
minimal bone. The pores were found to increase the flexibility of the CVOCA and enhance growth factor
release. Histological staining revealed that all three zones of hyaline cartilage were preserved within the
CVOCA. Chondrogenic growth factors (TGF-β1, TGF-β3, BMP-2, BMP-4, BMP-7, bFGF, IGF-1) and ECM proteins
(type II collagen, hyaluronan) were retained within the CVOCA, and their sustained release in culture was
observed (TGF β1, TGF-β2, aggrecan). The cells within the CVOCA were confirmed to be chondrocytes and
remained viable and functional post-thaw. Immunogenicity testing confirmed the absence of immunogenic
cells. The CVOCA induced MSC migration and chondrogenesis in vitro. Experimental results using devitalized
flash frozen osteochondral allografts revealed the importance of preserving all components of articular cartilage
in the CVOCA. Goats treated with the CVOCA and marrow stimulation exhibited better repair compared to
goats treated with marrow stimulation alone.
Conclusions: The CVOCA retains viable chondrocytes, chondrogenic growth factors, and ECM proteins within
the intact architecture of native hyaline cartilage. The CVOCA promotes MSC migration and chondrogenesis
following marrow stimulation, improving articular cartilage repair.
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Articular cartilage damage is a common orthopedic
problem, with more than 60 % of knee arthroscopies re-
vealing chondral or osteochondral defects [1, 2]. The
capacity for spontaneous articular cartilage repair is very
limited [3–6]. Therefore, several surgical options have
emerged to reduce pain and restore the structure and
function of injured articular cartilage. Marrow stimula-
tion, a reparative approach, and osteochondral allo-
grafts, a restorative approach, are commonly employed
techniques.
Marrow stimulation is often employed following de-
bridement to fill a lesion with repair tissue [5, 7]. In
marrow stimulation, the subchondral bone is penetrated
in order to introduce MSCs from the bone marrow into
the lesion to generate repair tissue. The initial blood clot
filling the lesion typically becomes fibrocartilage repair
tissue, with less type II collagen and reduced mechanical
integrity compared to normal, hyaline cartilage [8–10].
While marrow stimulation generally has good results in
young patients (<40 years old) with small lesions
(<2 cm2), the fibrocartilage often breaks down over time
leading to poor long-term outcomes, especially in older
patients and in lesions larger than 2 cm2 [8, 10–14]. Sev-
eral adjuncts to marrow stimulation have recently been
developed with the goal of directing the MSCs to be-
come chondrocytes that produce hyaline cartilage. Vari-
ous scaffolds, cells, and growth factors have been
studied for this purpose, but their clinical benefits are
not yet clearly defined.
Osteochondral allografting is a restorative procedure
in which a cadaveric graft consisting of articular cartilage
and its underlying subchondral bone is transplanted into
the defect. Osteochondral allografts can be used to treat
larger osteochondral lesions, but the procedure relies on
precise instrumentation to match the size and contours
of the donor tissue to the patient lesion. The clinical use
of fresh and fresh stored osteochondral allografts began
more than 40 years ago and has shown good results [7,
15]. As the implantation technique and selection criteria
have improved, long-term clinical success rates have in-
creased to 80–85 % on average, and above 95 % in more
recent studies of knee defect repair [16–20]. Currently,
fresh osteochondral allografts are stored at 4 °C in media
for approximately 14 days while microbiological screen-
ing and recipient matching is completed and are typically
used within 30 days, the time point when chondrocyte
viability begins to decline significantly [21–24]. The
short shelf life and size-matched donor availability
limit the use of fresh stored osteochondral allografts.
Frozen osteochondral allografts offer a longer shelf
life, but they lose chondrocyte viability and have a
higher likelihood of delaminating from the surround-
ing tissue [25, 26].Here, we present a new option that combines repara-
tive and restorative approaches for articular cartilage re-
pair. The cryopreserved, viable osteochondral allograft
(CVOCA) is a novel osteochondral allograft with only a
minimal amount of bone and pores spanning the thick-
ness of the allograft. The CVOCA builds upon more
than 40 years of safety and efficacy of fresh stored osteo-
chondral allografts as a restorative approach to articular
cartilage repair. In contrast to fresh stored osteochondral
allografts, the CVOCA can be stored frozen for up to
2 years, can fit to any surface contour, and can be im-
planted arthroscopically. In addition to increasing the
flexibility of the CVOCA, the pores enable the cryo-
preservation solution to penetrate the tissue to preserve
cell viability throughout rather than just at the surface,
as seen in previous attempts at cartilage cryopreserva-
tion [27]. When the CVOCA is used with marrow
stimulation, MSCs released from the bone marrow will
initiate a reparative response within the lesion in
addition to the restorative approach from the allograft
cartilage itself. The MSCs will be stimulated to undergo
chondrogenesis within the pores of the CVOCA and
produce type II collagen-rich hyaline repair tissue. In
this study, we characterize the CVOCA and provide data
supporting our hypothesis that the novel CVOCA can
improve articular cartilage repair when used with mar-
row stimulation.
Methods
Tissue procurement and CVOCA preparation
Human knees en bloc from 18 to 60-year-old donors that
were deemed as eligible for tissue donation for medical re-
search were shipped on wet ice and processed within
120 h post-mortem. Osteochondral plugs (20 mm and
10 mm in diameter, 1 to 3 mm thick) were harvested from
regions of healthy cartilage in the distal femur and prox-
imal tibia. Most of the osseous portion of each plug was
removed, leaving osteochondral allografts retaining the
entire thickness of hyaline cartilage and residual subchon-
dral bone. A score mark was added to the bone side of
each osteochondral allograft to maintain directionality.
Pores spanning the full thickness of the osteochondral al-
lografts were created. The CVOCAs were cryopreserved
in a DMSO-based solution using a controlled rate freezer
(Cryomed Model 7454) and stored at —80 °C. When
ready for testing, the CVOCAs were thawed in a 37 °C
water bath and rinsed in saline.
In designing the CVOCA, the importance of the pores
and their optimum size and density were investigated.
Pore diameters of 0.6 and 0.9 mm and densities of 12,
25, and 50 pores/cm2 were tested for flexibility. Six
blinded evaluators rated the flexibility of each CVOCA
on a scale from 1 to 5 (1 =most flexible, 5 = least flex-
ible). TGF-β1 release from the CVOCA (10-mm
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and without pores after a 7 day culture (in Dulbecco's
modified Eagle's medium (DMEM) with 10 % fetal bovine
serum (FBS), 2 % Glutamax, 2 % antibiotic-antimycotic)
was measured by ELISA (TGF-β1 Quantikine kit, R&D
Systems, Minneapolis, MN, USA).
Histological characterization and immunostaining of
CVOCA
The structure and extracellular matrix (ECM) contents
of the CVOCA were investigated through histological
staining of vertical cross sections. CVOCAs were fixed
in 4 % paraformaldehyde, decalcified in 10 % formic
acid, and embedded in paraffin. Serial 5-μm thick sec-
tions from the center of the CVOCA were stained with
hematoxylin and eosin (H&E), safranin O, and anti-
bodies for type I and type II collagen according to stand-
ard procedures. In negative control sections, normal
rabbit serum was substituted for the primary antibody.
Positive control sections included sections of normal
human articular cartilage (for type II collagen) and sub-
chondral bone (for type I collagen).
ELISA for ECM proteins in CVOCA
CVOCA tissue lysates and culture supernatants were an-
alyzed using ELISAs for the presence of ECM proteins.
CVOCAs were homogenized and the resulting tissue ly-
sates were analyzed using ELISA kits for type II collagen
(Astarte Biologics, Bothell, WA, USA) and hyaluronan
(R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s protocols. CVOCAs were cultured with
chondrocyte growth culture media (Lonza, Basel,
Switzerland) at 37 °C and 5 % CO2. Media collected after
1, 3, 7, and 14 days was analyzed using an aggrecan
ELISA kit (DIAsource ImmunoAssays, Louvain-la-
Neuve, Belgium) following the manufacturer’s protocol.
ELISA for chondrogenic growth factors in CVOCA
Chondrogenic growth factors were evaluated in CVOCA
tissue lysates using Quantikine and DuoSet ELISA kits
(R&D Systems, Minneapolis, MN, USA) for TGF-β1,
TGF-β3, BMP-2, BMP-4, BMP-7, bFGF, and IGF-1 fol-
lowing the manufacturer’s protocols. Culture superna-
tants were collected after 7, 14, and 21 days of CVOCA
culture at 37 °C and 5 % CO2 in chondrocyte growth
culture media (Lonza, Basel, Switzerland). The culture
supernatants were analyzed using DuoSet ELISA kits
(R&D Systems, Minneapolis, MN, USA) for TGF-β1,
TGF-β2, bFGF, and IGF-1 following the manufacturer’s
protocols. For comparison, the cells were devitalized in
some samples by freeze-thawing the CVOCAs three
consecutive times in a liquid nitrogen bath to create
flash frozen OCAs before use in the culture.Live/dead cell staining in CVOCA
Cell distribution and viability within the CVOCA were
investigated using live/dead cell staining. A scalpel blade
was used to cut thin horizontal tissue sections from the
superficial end of the CVOCAs. The sections were incu-
bated with a live/dead viability/cytotoxicity staining solu-
tion (Molecular Probes, Inc., Eugene, OR, USA) according
to the manufacturer’s instructions. Stained sections were
photographed under 100× magnification using a fluores-
cent microscope. Viable (green) and dead (red) cells
within three random fields were counted within each of
the CVOCA tissue sections. The counts from the three
fields were averaged, and the percentage of viable cells
was calculated for each CVOCA.
Isolation and analysis of cells from CVOCA
Cells were isolated by incubating minced CVOCAs with
a pronase digestion media (70 U/ml, Sigma, St. Louis,
Missouri, USA) for 1 h followed by a type I collagenase
digestion media (300 U/ml, Sigma, St. Louis, Missouri,
USA) for 3 h. Isolated cells were cultured in growth
media (DMEM/Ham’s F-12 with 10 % FBS, 50 μg/ml as-
corbic acid, 1 mg/ml glucose, and 0.2 % gentamicin) and
passaged three to five times.
The cellular composition within the CVOCA was in-
vestigated through fluorescence-activated cell sorting
(FACS). Cell suspensions were stained with phycoeryth-
rin (PE)-labelled antibodies to CD44, CD45, CD49e,
IgG1 (isotype control), or IgG2bκ (isotype control) (BD
Biosciences, San Jose, CA, USA) according to standard
procedures. The stained cells were evaluated using a sin-
gle color analysis on a FACSCalibur system with Cell-
Quest software (BD Biosciences, San Jose, CA, USA).
The cells isolated from the CVOCA were further char-
acterized by immunostaining in culture for type II colla-
gen and aggrecan according to standard protocols, with
rabbit polyclonal anti-type II collagen and mouse mono-
clonal anti-aggrecan (Abcam, Cambridge, UK) used as
the primary antibodies and Alexa Fluor 594 donkey anti-
rabbit and Alexa Fluor 488 rabbit anti-mouse (Invitrogen,
Grand Island, NY, USA) used as the secondary antibodies.
Primary antibodies were not included into staining for
negative control samples. All samples were stained with
DAPI (Roche, Basel, Switzerland) and analyzed with a
fluorescence microscope.
LPS-induced TNF-α secretion assay
Raw material (10-mm diameter osteochondral plugs with
approximately 5 mm of bone) and fully processed CVO-
CAs (10-mm diameter) sourced from the same donor were
cultured within wells of a 24-well plate in 2 ml of chondro-
cyte growth culture media (Lonza, Basel, Switzerland) per
well. The samples were exposed to bacterial lipopolysac-
charide (LPS) (1 μg/ml, Sigma, St. Louis, Missouri, USA)
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cells (hPBMCs) cultured with LPS (2 × 106 cells/well)
served as a positive control. Samples without LPS served
as background controls. After the 24-h culture period, the
media was collected and tested for the presence of TNF-α
using a TNF-α DuoSet ELISA kit (R&D Systems, Minneap-
olis, MN, USA) according to the manufacturer’s protocol.
In vitro mesenchymal stem cell migration assay
A transwell filter system was utilized to measure the mi-
gration of MSCs towards media conditioned with CVO-
CAs or flash frozen OCAs. The CVOCAs and flash
frozen OCAs (20-mm diameter) were cultured at 37 °C
and 5 % CO2 in 3 ml of media (DMEM+ 2 % antibiotic-
antimycotic) for 7 days to create the conditioned media.
DMEM was used as the negative control media while
DMEM+ 10 % FBS served as the positive control media.
Six hundred microliters of the media was placed within
wells of a 24-well plate. A 0.33-cm2 filter with 8-μm
pores was added to each well so the media filled the well
up to the filter. 1 × 105 human bone marrow-derived
MSCs at passage 3–5 were seeded on the top of each fil-
ter. After a 4-h culture, the MSCs that did not migrate
across the filters were removed from the top of each fil-
ter using cotton buds. The migrated MSCs were fixed
and stained with a 4 % paraformaldehyde/1 % gentian
violet solution. The migrated cells were visualized using
light microscopy. The migrated cells were then removed
from the bottom of each filter using 0.25 % trypsin-
EDTA, spun down, resuspended in DMEM, and counted
using a hemocytometer.
In vitro mesenchymal stem cell chondrogenesis assays
The ability of the CVOCA to induce MSC chondrogene-
sis was investigated using two in vitro CVOCA and
MSC co-culture assays. First, MSC pellets were co-
cultured with CVOCAs, but the two were not in direct
contact. 2.5 × 105 human bone marrow-derived MSCs at
passage 3–5 were pelleted into 15-ml conical tubes. A
basal media (incomplete chondrogenic induction media,
Lonza, Basel, Switzerland) was added to each tube. The
basal media alone served as the negative control while
the CVOCA (1/4 of 20-mm diameter CVOCA) was
added to each experimental tube so it resided within the
media but above the cell pellet for co-culture within the
conical tube. After 3 weeks of culture, the pellets were
sectioned and stained for type II collagen, using the
standard protocol. The percentage of each pellet cross
section that stained positive for type II collagen was cal-
culated using ImageJ (US National Institutes of Health,
Bethesda, Maryland, USA).
In order to mimic the in vivo microenvironment fol-
lowing microfracture and implantation of the CVOCA, a
second in vitro chondrogenesis assay was performedwhere MSCs were suspended in fibrin glue and spread
to fill the pores in the CVOCA with MSCs. Some of the
CVOCAs were flash frozen in liquid nitrogen, as de-
scribed previously. Each OCA (20-mm diameter) was
placed in a well within a 24-well plate and 4 × 106 hu-
man bone marrow-derived MSCs at passage 3–5 in
100 μl of fibrin glue were spread over the CVOCA. One
milliliter of complete or incomplete chondrogenic induc-
tion media (Lonza, Basel, Switzerland) was added to
each well. After 4 weeks, the samples were sectioned
vertically and horizontally and stained for type II colla-
gen. The percentage of pore cross sections that stained
positive for type II collagen was calculated using ImageJ
(US National Institutes of Health, Bethesda, Maryland,
USA).
CVOCA testing in a goat microfracture model
The CVOCAs were implanted in goats in order to dem-
onstrate safety and to investigate the time course of inte-
gration following implantation. Approval was obtained
from the Institutional Animal Care and Use Committee
(IACUC) of Thomas D. Morris, Inc. for the use of ani-
mals in this study. Young (<1 year old) Spanish goat
CVOCAs of 6-mm diameter were prepared using the
same methods that were developed for human tissue
processing. The goat CVOCAs were implanted in nine
skeletally mature (2–4 years old), female Spanish goats.
In each goat, two critical size cartilage defects (6 mm in
diameter) were created in the medial femoral condyle of
the right anterior knee joint using a biopsy punch and
cartilage dissection tools. The defects in 3 goats (6 de-
fects) were treated with marrow stimulation alone. The
defects in the remaining 6 goats (12 defects) were
treated with marrow stimulation augmented with the
CVOCA. Following marrow stimulation, the CVOCA
was secured in place by one of three methods: fibrin glue
below and above the CVOCA (6 defects), fibrin glue
above the CVOCA only (2 defects), or four 7-0 Vicryl
sutures spaced evenly around the CVOCA and through
the surrounding healthy cartilage (4 defects). The goats
were fitted with a modified Thomas splint and cast im-
mediately after surgery. The cast was removed after
21 days.
The goats were humanely euthanized after 3 months
(6 goats) and 12 months (3 goats) for analysis. Synovial
fluid was collected and evaluated for color and viscosity.
Popliteal lymph nodes were examined for inflammation.
The contralateral joint and the articulating surface op-
posing the defects were examined for any abnormalities
in each goat. An investigator blinded to the treatments
examined the operated joints, grading each lesion site
using the parameters outlined in Table 1. The sum of the
gross morphology scores was multiplied by the estimated
total percentage fill to assign each lesion a normalized
Table 1 Repair tissue gross morphology scoring parameters.
Parameters used to score goat repair tissue morphology. The
total score was multiplied by the total percentage of defect fill
to give the normalized grade score for each goat lesion
Characteristic Grading Score








Smoothness of the cartilage surface Present 2
Partial 1
None visible 0
Cartilage surface, degree of filling Present 2
Partial 1
None visible 0
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sections were taken through the center of the defects as
well as through medial and lateral edges of the defects
(1.5 cm from center). Serial sections were stained with
H&E and safranin O, and immunohistochemistry was per-
formed for type I and type II collagen. All stained sections
were imaged and analyzed by two independent, blinded
reviewers (SG and JQK) using the Pineda repair grading
system [28]. The reviewers’ scores from all three sites
(medial edge, center, lateral edge) were averaged to give
the overall histology scores for each lesion.
Statistical analysis
Each experiment was run on CVOCAs from multiple
donors. Data are presented as the mean ± standard error
of the mean (SEM). Comparisons between groups were
made using Student’s t-tests with significance at p < 0.05.Fig. 1 Appearance of CVOCA. Appearance of a CVOCA (20-mm diameter s
mark distinguishing the bottom (bone) side (outlined with black box in theResults
CVOCA design
The main goals in the novel CVOCA design were to
preserve all the benefits of a traditional fresh stored
osteochondral allograft including maintenance of the ar-
ticular cartilage structure and high chondrocyte viability,
while at the same time making it flexible, easy to im-
plant, compatible with arthroscopy, and able to have a
prolonged storage time. Only a minimal amount of bone
is kept to minimize damage to the patient’s subchondral
bone while still providing an anchor for bony integra-
tion. Additionally, reducing the amount of bone in the
CVOCA compared to traditional OCAs, along with the
added pores, allows the CVOCA to be flexible enough
to be implanted arthroscopically. The flexible allograft
can be easily sized and adapted to different contours
upon implantation (Fig. 1). The pores also enable the
cryopreservation solution to penetrate the CVOCA, main-
taining chondrocyte viability throughout the CVOCA ra-
ther than just at the surface. Additionally, the pores
provide a favorable chondrogenic microenvironment for
autologous MSCs, which are released from bone marrow
into the cartilage defect following a marrow stimulation
procedure and will reside within the CVOCA pores. The
viable hyaline cartilage within the CVOCA is expected to
provide the necessary signals to induce chondrogenesis of
MSCs released following marrow stimulation.
The pores were found to increase flexibility of the
CVOCA and to enhance growth factor release from the
CVOCA. The best flexibility score (2.2 ± 0.3) was assigned
to CVOCAs with the large pore size (0.9 mm) at the high-
est density (50 pores/cm2). The worst flexibility score (4.8
± 0.2) was assigned to CVOCAs with the small pore size
(0.6 mm) at the lowest density (12 pores/cm2). The CVO-
CAs with the large pore size (0.9 mm) at the medium
density (25 pores/cm2) were rated as the second most flex-
ible (3.0 ± 0.4). Based on these results, 1-mm diameter
pores at a density of 36 pores/cm2 were selected (Fig. 1).
Following a 7-day culture, it was observed that CVO-
CAs with pores released more TGF-β1 than CVOCAs
without pores (2,020 vs. 3,371 pg/ml). This boost mayize): top (left), bottom (middle), and side (right) views. Note the score
middle image) and the flexibility that enables folding (right image)
Fig. 2 CVOCA maintains hyaline cartilage structure and ECM contents. Histological stains of a representative cross section of the CVOCA show
that hyaline cartilage architecture (superficial, transitional, radial zones) and ECM contents (aggrecan, type II collagen) are maintained in the
CVOCA. Stains from left to right: Hematoxylin & Eosin, Safranin O, Type II Collagen, and Type I Collagen. The black arrow points to the tidemark,
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in surface area that the 1-mm pores at 36 pores/cm2
provide.
Extracellular matrix content
Histological staining of the CVOCA revealed that nor-
mal hyaline cartilage architecture and ECM contents
were preserved. The CVOCA retained the superficial,
transitional, and radial zones of hyaline cartilage and a
thin layer of subchondral bone (Fig. 2). The cellular
distribution and morphology, evident in the H&E stain,
are characteristic of chondrocytes within hyaline cartil-
age. The visible tidemark revealed that the transition
between cartilage and bone remained intact. The strong
red safranin O staining indicated the presence of a
proteoglycan-rich matrix. The CVOCA also stained
strongly for type II collagen. Analysis of CVOCA tissue




















Fig. 3 CVOCA releases aggrecan over time. Aggrecan content in
media collected from CVOCA culture at various time points. The
CVOCA released aggrecan for up to 14 days, which was the longest



























Fig. 4 CVOCA releases more TGF-β over time than flash frozen OCA.
TGF-β1 (A) and TGF-β2 (B) content in media collected from CVOCA
and flash frozen OCA culture at various time points. The CVOCA
releases more of the chondrogenic growth factors initially (day 7) and
over time (up to 21 days) relative to the flash frozen OCA. Data
presented as mean ± SEM for three independent experiments
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aggrecan released by the CVOCA into the culture media
increased significantly with each time point (p < 0.03)
(Fig. 3).
Growth factor content
Many of the growth factors that are important for cartilage
function, both in health and repair, were found to be
present within the tissue and secreted by the CVOCA.
Analysis of the CVOCA tissue lysates revealed that the
CVOCA contained TGF-β1 and TGF-β3, two growth fac-
tors that promote chondrogenic differentiation of MSCs
and regulate type II collagen expression in chondrocytes
[29]. The CVOCA tissue lysates contained BMP-2, BMP-4,
and BMP-7. These bone morphogenetic proteins are cap-
able of inducing MSC chondrogenesis and stimulating
ECM production by chondrocytes [29]. The CVOCA tissue
lysates also contained bFGF, a growth factor that stimulates
the proliferation of chondrocytes, and IGF-1, a growth fac-
tor that induces ECM synthesis in chondrocytes [29].
Both CVOCAs and flash frozen OCAs released increas-
ing amounts of TGF-β1 into the culture media with time
(Fig. 4a). CVOCAs released increasing amounts of TGF-
β2 into the culture media with time while flash frozen
OCAs followed the same trend except for a slight drop
in TGF-β2 release on day 14 (Fig. 4b). The CVOCAsFig. 5 Cells within the CVOCA are viable, functional chondrocytes. (A) Repr
from the top (superficial zone) of CVOCAs from four different donors. Live
represents 500 μm. (B) Representative FACS dot plots for the cell populatio
cut off point for negatively (left side) and positively (right side) stained cells.
CD49e and negative for the hematopoietic cell marker CD45. (C) Immunofl
CVOCA. Cells were stained for nuclei (blue, both images), type II collagen (rereleased more TGF-β1 and TGF-β2 than the flash fro-
zen OCAs at every time point. This difference was sta-
tistically significant at the day 7 time point for TGF-β1
release (p = 0.002).
Cellular content
As shown in Fig. 5a, the majority of the viable cells
within the CVOCA were retained after cryopreservation.
Tissue sections from the superficial zones of the CVO-
CAs contained 64,989 ± 7665 live cells/cm2 with a mean
cell viability of 70.5 % (range, 54.5–88.5 %). The percent-
age of viable cells in CVOCAs post-thaw was not differ-
ent from the fresh OCA controls from the same donors.
The viable cells that were isolated from the CVOCA
expressed the hyaluronan receptor CD44 and the fibro-
nectin and fibrinogen receptor CD49e, both chondrocyte
markers (Fig. 5b) [30, 31]. The cells were CD45-negative,
indicating that the population was free of hematopoietic
cells. The cultured cells that were isolated from the CVO-
CAs stained positively for type II collagen and aggrecan
(Fig. 5c), suggesting that the cells within the CVOCA are
viable, functioning chondrocytes.
Immunogenicity
The absence of immunogenic CD45-positive hematopoietic
cells within the CVOCA was shown by FACS analysisesentative images of live/dead staining in a transverse section taken
cells are stained green, and dead cells are stained red. The scale bar
n isolated from the CVOCA. The vertical lines on the graphs represent a
The population is positive for the chondrocyte markers CD44 and
uorescent staining of cultured cells that were isolated from the



















Fig. 6 Absence of immunogenic cells in the CVOCA. TNF-α
content in media collected following 24-h cultures of freshly
isolated osteochondral plugs (raw material), CVOCAs, and
hPBMCs (positive control) with and without LPS. TNF-α levels
were measured by ELISA. Data presented as mean ± SEM for
three independent experiments
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was further confirmed in the LPS-induced TNF-α
secretion assay. As depicted in Fig. 6, the TNF-α pro-
duction was negligible when the CVOCA was chal-
lenged by LPS (0.04 ± 0.04 pg/ml).CVOCA-induced mesenchymal stem cell migration
MSCs migrated across porous filters towards CVOCA
conditioned media (Fig. 7), indicating that the CVOCA re-
leases factors that are capable of recruiting MSCs. There
was a 3.1-fold greater recruitment of MSCs by the
































Fig. 7 CVOCA recruits MSCs. Total number of MSCs that migrated across p
(b) basal media, (c) COVCA conditioned media, (d) flash frozen OCA condit
from each condition showing the migrated MSCs on the bottom side of th
independent experimentsOCA conditioned media. The lower number of migrated
MSCs induced by the devitalized flash frozen OCAs was
likely due to the reduced growth factor release by the flash
frozen OCAs relative to the CVOCAs (Fig. 4).CVOCA-induced mesenchymal stem cell chondrogenesis
Chondrogenesis, as evidenced by type II collagen pro-
duction, was observed within MSC populations that
were co-cultured with the CVOCA (Fig. 8). 19.3 ± 4.3 %
of the MSC population cultured in pellets below the
CVOCA for 3 weeks stained positive for type II collagen.
In comparison, only 1.7 ± 1.3 % of MSCs in pellets cul-
tured alone were positive for type II collagen. This dif-
ference is statistically significant (p = 0.02), and these
data indicate that the CVOCA releases factors that pro-
mote MSC chondrogenesis. When the MSCs were cul-
tured in contact with the CVOCA (within the pores) for
4 weeks, a higher level of MSC chondrogenesis was ob-
served. 72.2 ± 3.3 % of MSCs cultured within pores of a
CVOCA with complete chondrogenic induction media
were positive for type II collagen (positive control).
When the MSCs were cultured within pores of the
CVOCA with incomplete chondrogenic induction media
(without chondrogenic growth factors), the CVOCAs re-
leased a sufficient amount of growth factors, inducing
chondrogenesis in 70.1 ± 4.7 % of MSCs. MSCs cultured
within pores of the flash frozen OCA demonstrated dif-
ferentiation (type II collagen staining) in 41.4 ± 3.0 % of
the population. This difference between the CVOCAs
and the flash frozen OCAs was statistically significant
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Fig. 8 CVOCA induces chondrogenesis of MSCs. Percentage of pellet (top) and pore (bottom) cross sections that stained positive for type II
collagen after culture (pellet—3 weeks, pores—4 weeks) along with representative images of type II collagen staining in pellets and pores
(vertical cross sections) from each culture condition (top – (a) basal media, (b) basal media + CVOCA, bottom – (a) flash frozen OCA in incomplete
media, (b) flash frozen OCA in complete media, (c) CVOCA in incomplete media, (d) CVOCA in complete media). Data presented as mean ± SEM
for two independent experiments
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high level of chondrogenic potential.
CVOCA facilitated cartilage repair in a goat microfracture
model
All goats remained clinically healthy and showed no
local or systemic effects after the surgery. Upon examin-
ation after sacrifice, there was no evidence of infection
or inflammation and synovial fluid appeared normal in
all animals. Any degenerative changes between the oper-
ated and contralateral knee were generally matched for
the medial femoral condyle, condyle groove junction,
femoral groove, and proximal tibia and were not unusual
for the animal’s age and species [32].
As shown in Fig. 9, the normalized grade scores for
the lesions treated with marrow stimulation plus the
CVOCA were higher than the scores for the lesions
treated with marrow stimulation alone, demonstratingthat the use of the CVOCA resulted in improved gross
morphology. This difference was statistically significant
at 3 months when the lesion treated with CVOCA was
filled with repair tissue while the lesion treated with
marrow stimulation alone was largely unfilled (p =
0.006). The normalized grade score for lesions treated
with the CVOCA increased significantly from 3 to
12 months as well (p = 0.02). By 12 months, boundaries
of the CVOCA were no longer distinguishable due to
the complete integration of the implanted CVOCA with
the repair tissue filling the pores and the surrounding
host tissue. This integration is reflected in the maximum
possible edge integration score (2.0) within the normal-
ized grade score that the goats treated with the CVOCA
received. The lesions treated with marrow stimulation
alone had less overall lesion fill at 12 months than the
lesions treated with the CVOCA, but the repair tissue
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Fig. 9 Gross appearance and analysis of lesions in goat model at time of implantation and at 3 and 12 months. Appearance of lesions treated
with marrow stimulation alone (top left) and marrow stimulation plus implantation of a CVOCA (top right) at time of surgical intervention.
Normalized grade scores for repair tissue in lesions treated with marrow stimulation alone at 3 months (a) and 12 months (c) or marrow
stimulation plus the CVOCA at 3 months (b) and 12 months (d), along with representative images of repair tissue in lesions from each condition
and time point (bottom). The maximum normalized grade score possible is 10. The bar graph shows mean ± SEM
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The Pineda histological scoring system addresses
four parameters of cartilage repair quality with overall
scores ranging from 0 for normal, healthy tissue to 14
for abnormal, damaged tissue [28]. Pineda scores
improved significantly for lesions treated with the
CVOCA from 6.0 ± 0.8 at 3 months to 2.0 ± 0.6 at
12 months (p = 0.003). The reduction in Pineda scores
over time was also significant for lesions treated with
marrow stimulation alone (7.8 ± 0.7 at 3 months, 3.2 ±
0.2 at 12 months, p = 0.006). The scores for defect fill-
ing, one of the four parameters that make up the over-
all Pineda score, were significantly lower for the
lesions treated with the CVOCA at both time points
(p < 0.05). At 3 months, the scores for cell morphology,
the measure of hyaline tissue in the Pineda system,
were also significantly lower for lesions treated with
the CVOCA (p = 0.04).
The cartilage lesions treated with the CVOCA were
filled with highly cellular, hyaline-like repair tissue at3 months post-surgery. At both 3 and 12 month time
points, the repair tissue contained primarily type II col-
lagen, with a small amount of type I collagen, and the
implanted CVOCA completely integrated with the sur-
rounding tissue. By 12 months, aggrecan content in-
creased and cellular morphology and distribution were
comparable to the morphology and distribution of cells
within normal cartilage, with more rounded cells in
the superficial zone and a columnar formation in the
transitional and radial zones (Fig. 10). The formation
of a new tidemark marked the good integration be-
tween the CVOCA implant and the host subchondral
bone.
At the 3-month time point, when different methods
for implanting the CVOCA were tested, all gross and
histological scores were better when either fibrin glue
above the CVOCA or sutures were used, rather than
fibrin glue below and above the CVOCA. For this rea-
son, it is recommended that the CVOCA is implanted
in direct contact with the subchondral bone for clin-
ical use.
Fig. 10 CVOCA repair tissue histology in goat model at 12 months. Representative histological stains of host and repair tissue in lesion treated
with marrow stimulation plus the CVOCA at 12 months post-intervention. Sections were taken through the center of the lesion, and the scale bars
represent 1 mm. The enlarged H&E image shows the border between the host and repair tissues and highlights the cellular organization and
tidemark configuration in both tissues
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In this study, we described the design and characteristics
of a novel, cryopreserved, viable osteochondral allograft
(CVOCA). Several goals were achieved in designing the
CVOCA including flexibility, ease of use, a long storage
time, and preservation of the structural matrix, growth
factors, and viable chondrocytes. In addition, the CVOCA
design allows it to be used in combination with marrow
stimulation for articular cartilage repair.
Following a marrow stimulation procedure and im-
plantation of the CVOCA, it is hypothesized that blood
containing bone marrow MSCs will fill the pores of the
CVOCA, forming stable clots within each pore. The
growth factors released by the CVOCA will continue to
recruit bone marrow MSCs towards the CVOCA over
time. The CVOCA will not only serve as a scaffold for
the MSCs, but the viable chondrocytes in the CVOCA
will continually release growth factors into the sur-
rounding microenvironment, influencing the MSCs to
undergo chondrogenesis and produce hyaline repair tis-
sue within the pores.
Over time, the reparative response initiated within the
lesion is expected to not only fill in the pores of the
CVOCA but also to integrate the border between the
CVOCA and the host cartilage surrounding the defect.
The residual bone in the CVOCA will help to anchor
the allograft to the host bone through creeping substitu-
tion and re-vascularization, similar to the repair seenwith traditional fresh stored osteochondral allografts [33,
34]. In this manner, the CVOCA is expected to result in
a combination of allogeneic and autologous hyaline car-
tilage filling the lesion, strongly integrated with sur-
rounding cartilage and underlying bone.
Here, we characterized the structure and contents of
the CVOCA and provided in vitro and in vivo evidence
supporting our hypothesis, demonstrating how the
CVOCA works to augment marrow stimulation to im-
prove articular cartilage repair. Histological staining re-
vealed that the structure of the native hyaline cartilage is
preserved and a thin layer of subchondral bone is
present within the CVOCA. The CVOCA retains and
secretes ECM proteins and growth factors that are typic-
ally found in hyaline cartilage. The CVOCA was non-
immunogenic and contained viable chondrocytes that
stained positive for aggrecan and type II collagen. Func-
tionally, the CVOCA induces MSC migration and triggers
MSC chondrogenesis. The highest level of chondrogenesis
in vitro was seen when the MSCs were cultured within the
pores of the CVOCA. These results support the hypoth-
esis that the CVOCA can induce chondrogenesis of MSCs
recruited from the bone marrow and trapped within the
CVOCA pores following marrow stimulation, producing
type II collagen and restoring damaged cartilage.
Including flash frozen OCAs, which do not contain vi-
able chondrocytes, in some of our experiments revealed
the importance of preserving all components of the
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OCA showed decreased growth factor release, MSC mi-
gration, and MSC chondrogenesis relative to the
CVOCA with preserved living cells. These results indi-
cate that viable chondrocytes continue to secrete growth
factors, contributing to the persistence of growth factor
secretion over time from the CVOCA and the resulting
increase in MSC migration and chondrogenesis. The
high percentage of viable cells preserved within the
CVOCA (70.5 %) is a significant improvement compared
to previous attempts at cartilage cryopreservation that
resulted in only 20–50 % viable cells and, due to the
known importance of viable cells for graft performance,
prevented cryopreserved osteochondral allografts from
gaining widespread use in the past [35–37].
The in vivo goat study further supports our hypothesis
that the CVOCA improves repair compared to marrow
stimulation alone. Defect filling and gross tissue appear-
ance of lesions treated with marrow stimulation aug-
mented with the CVOCA were superior (significantly
higher normalized grade scores) to lesions treated with
marrow stimulation alone at 3 months, suggesting that
the CVOCA facilitates a faster repair than marrow
stimulation alone. Histologically, the pores of the CVOCA
were completely filled with highly cellular, type II collagen
and proteoglycan-rich repair tissue at 3 months. By
12 months, gross and histological analyses showed inte-
gration of the implanted CVOCA with the host cartilage
and bone. The goats treated with marrow stimulation
alone had less lesion fill and zonal organization within the
repair tissue. The study also demonstrated that the pre-
ferred fixation technique of the CVOCA is to suture or
apply fibrin glue around the periphery or over the top of
the CVOCA rather than at the base of the lesion. We
hypothesize that the fibrin glue beneath the CVOCA re-
duces infiltration of host MSCs and inhibits integration
with the subchondral bone and should therefore be
avoided.
Our in vitro and in vivo data are validated by a recent
clinical case [38]. In this case study, the first document-
ing clinical use of the CVOCA, Hoffman et al. described
a biopsy that was collected 9 months following implant-
ation of the CVOCA in a 10-mm diameter trochlear de-
fect. Histological staining of the biopsy showed 85 %
hyaline cartilage repair tissue with strong type II colla-
gen and proteoglycan staining, good cellularity, and a
replicated tidemark. The pores of the CVOCA appeared
filled upon inspection, and the patient reported reso-
lution of pain and return to normal activity.
Clinically, the CVOCA has been used both as an ad-
junct to marrow stimulation and as a primary repair
without deep marrow stimulation, more similar to a
traditional osteochondral allograft. In the latter case, de-
bridement of the cartilage and subchondral bone isperformed until a bleeding bed is created within the le-
sion. The bleeding bed results in the formation of a
blood clot that may help with integration of the im-
planted CVOCA. It is hypothesized that cartilage repair
with the CVOCA will be mediated by the same mecha-
nisms known for fresh stored osteochondral allografts.
The CVOCA has a thin layer of bone which assists in
integration with the patient’s own subchondral bone.
However, the bone portion in the CVOCA was further
reduced compared to fresh stored OCAs to enable the
CVOCA to be flexible and to minimize damage to a pa-
tient’s healthy subchondral bone. Additional benefits to
the CVOCA compared to fresh stored osteochondral al-
lografts include a longer shelf life and no requirement
for donor matching.
Conclusions
A novel cryopreserved viable osteochondral allograft
(CVOCA), with pores and a reduced bone portion com-
pared with a traditional osteochondral allograft, has been
developed. The CVOCA maintains the structure and
contents of native hyaline cartilage (ECM, growth fac-
tors, chondrocytes). This CVOCA induces MSC migra-
tion and chondrogenesis that can improve repair
following a bone marrow stimulation procedure. Unique
attributes of the CVOCA include its flexibility to fit de-
fects of any shape and contour, a straightforward im-
plantation technique, and a long shelf life that enables
point of care use within a single surgery.
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